GlassScriptPhysician profile
James Christopher Dean
NPI 1083618532
$11,916.78
in general payments reported to CMS, 2019-2025
29 companies · $1,588 in 2025
The $1,588 reported for 2025 was more than what 85% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $688 · 2020: $556 · 2021: $1,413 · 2022: $3,257 · 2023: $1,341 · 2024: $3,074 · 2025: $1,588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,601 · Travel and Lodging: $1,236 · Education: $99.99 · Honoraria: $38.86 · Gift: $27.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,600.53 |
| Travel and Lodging | $1,235.58 |
| Education | $99.99 |
| Honoraria | $38.86 |
| Gift | $27.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $3,303.13 | 2022-2024 | |
| Rxsight INC | $1,359.05 | 2022-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Injector Handpiece |
| Abbvie INC. | $1,255.54 | 2022-2025 | Durysta, Alphagan P, Lumigan |
| Allergan, INC. | $1,080.60 | 2019-2022 | |
| Alcon Vision LLC | $1,036.92 | 2019-2025 | Rocklatan, Tryptyr, Rhopressa |
| Mallinckrodt Hospital Products INC. | $731.37 | 2021-2023 | Acthar |
| Sun Pharmaceutical Industries INC. | $345.82 | 2019-2025 | Cequa |
| Harrow Eye, LLC | $312.19 | 2023-2025 | Iheezo, Vevye |
| Oyster Point Pharma, INC. | $300.65 | 2022-2025 | Tyrvaya |
| Kala Pharmaceuticals, INC. | $299.92 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $288.06 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Ocular Therapeutix, INC. | $221.80 | 2021-2025 | Dextenza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $200.23 | 2019-2021 | |
| Dompe US, INC. | $184.77 | 2022-2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $153.70 | 2019-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $139.45 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $120.62 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $105.88 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $100.95 | 2024 | Idose |
| Amgen INC. | $74.10 | 2025 | Tepezza |
| Hoffmann-La Roche Limited | $69.10 | 2019 | |
| Biotissue Holdings INC. | $46.25 | 2022-2025 | |
| Sight Sciences, INC. | $41.90 | 2021-2022 | |
| Quidel Corporation | $40.70 | 2019-2020 | |
| Merz Pharmaceuticals, LLC | $28.92 | 2022 | |
| Eyevance Pharmaceuticals LLC | $26.01 | 2019-2022 | |
| Horizon Therapeutics Plc | $16.87 | 2022 | |
| Rayner Intraocular Lenses Limited | $16.83 | 2022 | |
| Johnson & Johnson Vision Care, INC. | $15.45 | 2023 | Acuvue |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Dean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.